Entities / Company
Madrigal Pharmaceuticals (United States).
company in West Conshohocken, United States
- Reports this week
- 0
- Active events
- 1
- Connections
- 32
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
Gone quiet
No new reports in 90+ days-
Artisan Small Cap Fund highlighted Madrigal Pharmaceuticals stock.Some support1 report1 development inside
-
Madrigal Pharmaceuticals' Rezdiffra, the first medication for MASH, is mentioned in the context of Trump-era tariffs and AI stock trends.Speculative1 report
-
Madrigal Pharmaceuticals received EMA endorsement on 2025-06-21, allowing market entry in Europe.Speculative1 report
-
Madrigal Pharmaceuticals received FDA approval for its drug Rezdiffra, which targets MASH. The company also participated in a conference hosted by Morgan Stanley.Well supported10 reports
-
Madrigal Pharmaceuticals entered an exclusive global license agreement for SYH2086, a potential best-in-class MASH treatment.Some support1 report
-
Madrigal Pharmaceuticals' Rezdiffra received authorization for MASH from the European Commission, prompting analyst price target increases.Some support6 reports
No events began in the chosen period. Widen it, or reset.
Around Madrigal Pharmaceuticals (United States) this week
News at the entities that move Madrigal Pharmaceuticals (United States) most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Madrigal Pharmaceuticals (United States)
-
Europe Shared contextThe European Central Bank is forced to raise interest rates due to energy price shocks from the Iran war and an influx of Chinese exports.Moves Madrigal Pharmaceuticals (United States)
Connections
The 3 strongest of 32, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
Madrigal Pharmaceuticals' market entry and function are structurally dependent on receiving regulatory approval from the FDA.
-
Europe Shared context
Madrigal Pharmaceuticals is seeking and achieving market approval and expansion within the European market.
-
Mash Mentioned together
No evidence was found in the timeline linking Madrigal Pharmaceuticals and Mash.
History
Events by the month they beganJune 2026
8 events- Novo Nordisk's Wegovy received FDA approval for treating MASH, posing a competitive challenge to Madrigal Pharmaceuticals' Rezdiffra.
- Madrigal Pharmaceuticals is focusing on novel therapeutics for MASH and has secured a $500 million credit facility.
- Artisan Small Cap Fund highlighted Madrigal Pharmaceuticals stock.
- Madrigal Pharmaceuticals' Rezdiffra, the first medication for MASH, is mentioned in the context of Trump-era tariffs and AI stock trends.
- Madrigal Pharmaceuticals received EMA endorsement on 2025-06-21, allowing market entry in Europe.
- Madrigal Pharmaceuticals received FDA approval for its drug Rezdiffra, which targets MASH. The company also participated in a conference hosted by Morgan Stanley.
- Madrigal Pharmaceuticals entered an exclusive global license agreement for SYH2086, a potential best-in-class MASH treatment.
- Madrigal Pharmaceuticals' Rezdiffra received authorization for MASH from the European Commission, prompting analyst price target increases.